title: The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.
abstract: The hippocampo-prefrontal (H-PFC) pathway has been linked to cognitive and emotional disturbances in several psychiatric disorders including schizophrenia. Preclinical evidence from the NMDA receptor antagonism rodent model of schizophrenia shows severe pathology selective to the H-PFC pathway. It is speculated that there is an increased excitatory drive from the hippocampus to the prefrontal cortex due to dysfunctions in the H-PFC plasticity, which may serve as the basis for the behavioral consequences observed in this rodent model. Thus, the H-PFC pathway is currently emerging as a promising therapeutic target for the negative and cognitive symptom clusters of schizophrenia. Here, we have reviewed the physiological, pharmacological and functional characteristics of the H-PFC pathway and we propose that allosteric activation of glutamatergic and cholinergic neurotransmission can serve as a plausible therapeutic approach.
authors.affiliation: Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 0697, USA.
authors.forename: Ayan
authors.initials: A
authors.lastname: Ghoshal
authors.affiliation: Vanderbilt Center for Neuroscience Drug Discovery, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232 0697, USA.
authors.forename: P Jeffrey
authors.initials: PJ
authors.lastname: Conn
keywords: NMDA antagonist; hippocampus; plasticity; prefrontal cortex; schizophrenia
references.citation: J Neurosci. 2005 Sep 28;25(39):8854-66
references.pmid: 16192375
references.citation: J Physiol Paris. 2013 Dec;107(6):441-7
references.pmid: 23719128
references.citation: Curr Biol. 1999 Nov 18;9(22):R848-50
references.pmid: 10574750
references.citation: Trends Pharmacol Sci. 2009 Mar;30(3):148-55
references.pmid: 19201489
references.citation: Nat Chem Biol. 2008 Jan;4(1):42-50
references.pmid: 18059262
references.citation: Cereb Cortex. 2004 Feb;14(2):224-9
references.pmid: 14704220
references.citation: Hippocampus. 2010 Aug;20(8):906-10
references.pmid: 20095006
references.citation: Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8467-72
references.pmid: 15159546
references.citation: J Physiol Paris. 2013 Dec;107(6):434-40
references.pmid: 23792022
references.citation: Neuroreport. 1995 Oct 2;6(14):1845-8
references.pmid: 8547581
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1942-7
references.pmid: 19171889
references.citation: Science. 1998 Aug 28;281(5381):1349-52
references.pmid: 9721099
references.citation: J Neurosci. 1997 Mar 1;17(5):1880-90
references.pmid: 9030646
references.citation: Eur J Neurosci. 1999 Nov;11(11):4145-8
references.pmid: 10583503
references.citation: Behav Brain Res. 2011 Jun 1;219(2):205-12
references.pmid: 21238490
references.citation: Annu Rev Physiol. 2002;64:355-405
references.pmid: 11826273
references.citation: Neuropharmacology. 2013 Feb;65:143-55
references.pmid: 23022398
references.citation: Eur J Pharmacol. 2005 Sep 5;519(1-2):114-7
references.pmid: 16099452
references.citation: Eur J Neurosci. 1992;4(12):1285-1295
references.pmid: 12106392
references.citation: J Neurosci. 2000 Nov 15;20(22):RC106
references.pmid: 11069975
references.citation: Behav Brain Res. 2009 Dec 7;204(2):396-409
references.pmid: 19110006
references.citation: Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):1-16
references.pmid: 12769631
references.citation: Eur Neuropsychopharmacol. 2013 Oct;23(10):1165-81
references.pmid: 23332457
references.citation: Neuroreport. 2001 May 8;12(6):1191-3
references.pmid: 11338190
references.citation: Neurobiol Learn Mem. 2008 May;89(4):560-6
references.pmid: 18039585
references.citation: J Neurosci. 2007 Oct 24;27(43):11496-500
references.pmid: 17959792
references.citation: Behav Brain Res. 2008 May 16;189(1):152-8
references.pmid: 18282619
references.citation: Neurosci Lett. 2003 May 22;342(3):179-82
references.pmid: 12757894
references.citation: J Psychopharmacol. 2007 Mar;21(2):198-205
references.pmid: 17329300
references.citation: Psychopharmacology (Berl). 2007 Sep;193(4):521-37
references.pmid: 17497138
references.citation: PLoS Biol. 2005 Dec;3(12):e402
references.pmid: 16279838
references.citation: J Neurosci. 2009 Nov 11;29(45):14271-86
references.pmid: 19906975
references.citation: Neuroscience. 1999;94(4):1019-27
references.pmid: 10625044
references.citation: J Neurosci. 2011 Nov 23;31(47):17269-77
references.pmid: 22114293
references.citation: Neuron. 2010 Jun 24;66(6):921-36
references.pmid: 20620877
references.citation: Neurosci Lett. 1990 Jul 3;114(2):184-90
references.pmid: 2395531
references.citation: Brain Res. 2002 Aug 16;946(2):314-22
references.pmid: 12137936
references.citation: Nat Rev Drug Discov. 2009 Jan;8(1):41-54
references.pmid: 19116626
references.citation: Pharmacol Biochem Behav. 2008 Jan;88(3):272-9
references.pmid: 17904209
references.citation: J Med Chem. 2014 May 22;57(10):4154-72
references.pmid: 24735492
references.citation: Eur J Neurosci. 2004 Jul;20(2):514-24
references.pmid: 15233760
references.citation: Cereb Cortex. 2008 Jun;18(6):1407-14
references.pmid: 17934187
references.citation: Neurosci Lett. 2003 May 1;341(2):143-6
references.pmid: 12686386
references.citation: Neuroscience. 2007 Dec 5;150(2):442-8
references.pmid: 17935894
references.citation: Psychopharmacology (Berl). 2008 May;198(1):141-8
references.pmid: 18311557
references.citation: Behav Brain Res. 2008 Aug 5;191(1):26-31
references.pmid: 18453008
references.citation: Neuropharmacology. 2009 Mar;56(4):788-97
references.pmid: 19705572
references.citation: Eur J Neurosci. 1990 Oct;2(11):960-972
references.pmid: 12106083
references.citation: Neuroscience. 2008 Jun 2;153(4):1309-19
references.pmid: 18455317
references.citation: J Neurophysiol. 1997 Aug;78(2):1155-60
references.pmid: 9307143
references.citation: Brain Res Bull. 2007 Mar 30;71(6):601-9
references.pmid: 17292803
references.citation: Schizophr Bull. 2012 Jan;38(1):9-14
references.pmid: 21965469
references.citation: J Neurosci. 2011 Dec 14;31(50):18464-78
references.pmid: 22171048
references.citation: Neuroreport. 2002 Mar 25;13(4):469-72
references.pmid: 11930163
references.citation: Psychopharmacology (Berl). 2008 Feb;196 (2):269-80
references.pmid: 17940750
references.citation: Cereb Cortex. 2005 May;15(5):663-9
references.pmid: 15342431
references.citation: Neuron. 2012 Nov 21;76(4):804-12
references.pmid: 23177964
references.citation: Behav Neurosci. 2005 Apr;119(2):420-8
references.pmid: 15839788
references.citation: Eur Neuropsychopharmacol. 2014 May;24(5):822-35
references.pmid: 24287012
references.citation: Neuroscience. 1987 Sep;22(3):849-62
references.pmid: 3683852
references.citation: Cereb Cortex. 2015 May;25(5):1348-61
references.pmid: 24304584
references.citation: Eur J Pharmacol. 2009 Jan 5;602(1):78-84
references.pmid: 19026629
references.citation: Pharmacol Ther. 2010 Dec;128(3):419-32
references.pmid: 20705091
references.citation: Neuron. 2009 Feb 26;61(4):587-96
references.pmid: 19249278
references.citation: Schizophr Res. 2012 Mar;135(1-3):112-5
references.pmid: 22260963
references.citation: J Comp Neurol. 1996 May 20;369(1):1-15
references.pmid: 8723699
references.citation: Brain Res Brain Res Rev. 2000 Mar;31(2-3):302-12
references.pmid: 10719157
references.citation: Neuroscience. 2002;114(3):769-79
references.pmid: 12220577
references.citation: J Neurosci. 2007 Mar 14;27(11):2781-7
references.pmid: 17360899
references.citation: Br J Pharmacol. 2001 Feb;132(4):799-806
references.pmid: 11181420
references.citation: Neuroreport. 2010 Jan 6;21(1):68-72
references.pmid: 19996810
references.citation: Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14120-5
references.pmid: 19666562
references.citation: Behav Brain Res. 2007 Nov 22;184(1):31-8
references.pmid: 17675172
references.citation: Hippocampus. 1997;7(4):397-402
references.pmid: 9287079
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2009 Nov 13;33(8):1464-73
references.pmid: 19666074
references.citation: Eur J Neurosci. 1995 Feb 1;7(2):247-50
references.pmid: 7757261
references.citation: J Neurosci. 2010 Dec 15;30(50):17102-10
references.pmid: 21159980
references.citation: Eur J Neurosci. 2005 Feb;21(4):1070-6
references.pmid: 15787711
references.citation: Brain Res. 1989 Dec 29;505(2):337-40
references.pmid: 2598054
references.citation: Brain Res. 1984 Jun 8;302(2):257-65
references.pmid: 6733513
references.citation: Brain Res. 1988 Feb 23;442(1):11-22
references.pmid: 3359247
references.citation: Neuropharmacology. 2003 Mar;44(4):462-72
references.pmid: 12646283
references.citation: Brain Res. 2002 Sep 13;949(1-2):131-8
references.pmid: 12213308
references.citation: Cereb Cortex. 2000 Mar;10(3):206-19
references.pmid: 10731217
references.citation: J Neurosci. 2011 Jul 20;31(29):10721-31
references.pmid: 21775615
references.citation: J Neurosci. 2014 Jul 2;34(27):9059-66
references.pmid: 24990926
references.citation: Neurosci Lett. 2003 Jul 10;345(1):69-71
references.pmid: 12809991
references.citation: J Comp Neurol. 1991 Nov 22;313(4):574-86
references.pmid: 1783682
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2004 Dec;28(8):1267-77
references.pmid: 15588753
references.citation: Neuron. 2011 Oct 6;72(1):153-65
references.pmid: 21982376
references.citation: ACS Chem Neurosci. 2014 Oct 15;5(10):920-42
references.pmid: 25137629
references.citation: J Physiol. 2009 Nov 1;587(Pt 21):5139-47
references.pmid: 19752120
references.citation: J Physiol Paris. 1996;90(5-6):361-6
references.pmid: 9089514
references.citation: Arch Gen Psychiatry. 2005 Apr;62(4):379-86
references.pmid: 15809405
references.citation: J Psychopharmacol. 2003 Mar;17(1):57-65
references.pmid: 12680740
references.citation: Brain Res. 1982 Aug 12;245(2):267-74
references.pmid: 6289964
references.citation: Int J Neuropsychopharmacol. 2010 Oct;13(9):1219-31
references.pmid: 20128952
references.citation: Cereb Cortex. 2003 Jul;13(7):782-92
references.pmid: 12816894
references.citation: Mol Pharmacol. 2010 Dec;78(6):1105-23
references.pmid: 20923853
references.citation: Hippocampus. 2001;11(5):569-77
references.pmid: 11732709
references.citation: J Psychopharmacol. 2008 Nov;22(8):918-22
references.pmid: 18208936
references.citation: Neuropharmacology. 2004 Aug;47(2):195-204
references.pmid: 15223298
references.citation: Schizophr Res. 2008 Mar;100(1-3):120-32
references.pmid: 18234476
references.citation: Neuroreport. 2003 Dec 2;14(17):2225-8
references.pmid: 14625452
references.citation: Bioorg Med Chem Lett. 2014 Jun 15;24(12):2693-8
references.pmid: 24794112
references.citation: Behav Brain Res. 2006 May 15;169(2):263-73
references.pmid: 16500717
references.citation: J Physiol Paris. 2013 Dec;107(6):448-51
references.pmid: 23603055
references.citation: Brain Res Rev. 2007 Nov;56(1):1-26
references.pmid: 17559940
references.citation: J Pharmacol Exp Ther. 1991 Aug;258(2):728-38
references.pmid: 1865369
references.citation: J Neurosci. 2001 Aug 15;21(16):5925-34
references.pmid: 11487615
references.citation: Cereb Cortex. 2010 Feb;20(2):393-403
references.pmid: 19515741